Q2 2025 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Madrigal Pharmaceuticals Inc (MDGL) reported strong financial performance with net sales of $213 million in the second quarter, up 55% quarter-over-quarter.
- Rezdiffra's quarterly run rate now exceeds $200 million, positioning it well on its way to achieving blockbuster status.
- The company secured a new US patent for Rezdiffra, extending protection to February 2045, which significantly enhances its long-term growth potential.
- Madrigal Pharmaceuticals Inc (MDGL) is preparing for international expansion, starting with Germany, which presents a new growth opportunity.
- The company has entered into a global licensing agreement for an oral GLP-1, SYH2086, to combine with Rezdiffra, aiming to develop a best-in-disease oral combination for MASH.
- Gross-to-net dynamics are expected to be choppy, with potential increases in discounts in the second half of the year.
- Operating expenses are anticipated to rise modestly in the third and fourth quarters, driven by commercial launch activities.
- The competitive landscape is intensifying with the potential entry of GLP-1 therapies, which may impact pricing and market dynamics.
- There is uncertainty regarding the impact of payer strategies, such as step edits, which could affect Rezdiffra's market penetration.
- The company has not provided revenue guidance for the near term, creating some uncertainty about future financial performance.
Good morning, and thank you for standing by. Welcome to Madrigal Pharmaceuticals second quarter 2025 earnings conference call.
(Operator Instructions) As a reminder, today's conference call is being recorded.
I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.
Thank you, Demi. Good morning, everyone, and thank you for joining us to discuss Madrigal's second quarter 2025 earnings. We issued a press release this morning and posted a slide deck that accompanies this webcast on the Investor Relations section of our website.
On the call with me today is Bill Sibold, Chief Executive Officer; Dave Soergel, Chief Medical Officer; and Mardi Dier, Chief Financial Officer. They'll provide prepared remarks, and then we'll take your questions.
Please note on slide 2, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the risks that may cause actual results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
